Global Vaginal Anti Infectives Market, By Type (Antifungal, Antibacterial, Antiviral, Others), Product (Creams, Pessaries (Tablets), Gels, Solutions, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Vaginal Anti Infectives Market Analysis and Size
The global vaginal anti infectives market is expected to witness significant growth during the forecast period. Vaginitis is a common type of infection. Bacterial vaginitis, fungal vaginitis (yeast infection), and trichomoniasis are the most frequent kinds of vaginitis. everal reasons can cause vaginal infections such as poor sanitizing condition, unhygienic toilet usage and sexual infection will also boost up the vaginal anti-infectives market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in global vaginal anti infectives market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Vaginal anti-infectives are the type of agents that are used for the killing or supressing the infection of vagina caused by numerous bacteria, virus, fungi or micro-organism. These bacteria and others invade the host by means of its replication or releasing several toxins into the host. "Yeast" infections, tyrichomoniasis vaginitis, bacterial vaginosis, chlamydia vaginitis, and viral vaginitis are the major forms of vaginitis. About one third women all over the world experience indications of vaginitis at some point in their lifetime. Women are highly prone to vaginitis during the reproductive age; a change in the balance of bacteria and yeast present in vagina can lead to vaginitis.
Vaginal Anti Infectives Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Antifungal, Antibacterial, Antiviral, Others), Product (Creams, Pessaries (Tablets), Gels, Solutions, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Hikma Pharmaceuticals plc (U.K.), Aurobindo Pharma (India), AbbVie Inc. (Ireland), Melinta Therapeutics, Inc (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Lupin (India), Perrigo Company plc (U.S.)
|
|
Market Opportunities
|
|
Global Vaginal Anti Infectives Market Dynamics
Drivers
- Increased Strategic Collaborations and Initiatives
Growing inorganics strategies such as business expansion adopted by the numerous market players are expected to boost the growth of the global vaginal anti infectives market during the forecast period. For instance, in June 2016, Bausch Health Companies Inc. announced that its subsidiary Valeant Canada is increasing its manufacturing and export capacity in Canada.
- Growing Healthcare Facilities
Numerous established healthcare infrastructures, as well as the increased frequency of disease and the occurrence of significant manufacturers, are the primary factors that contributes to the market share. For instance, Gedea created pHyph discovered a pill that helps restore vaginal acidity in the first instance.
Opportunities
- Increased Product Launches
Major market players in the market are primarily focused on product launches in the market, that is expected to boost the market growth during the forecast period. For instance, in December 2016, Dr. Reddy’s Laboratories Ltd. launched Nystatin and Triamcinolone Acetonide Cream, USP, which the U.S FDA approved .in the U.S. This boosts the market growth.
- Increasing Demand for Retail Pharmacies
The rise in the number of vaginal anti infectives delivered through retail pharmacies and the increase in the number of retail pharmacies in highly advanced countries create much opportunities for the market growth. In addition, patients choose retail pharmacies to purchase drugs, as these are easily accessible.
Restraints/Challenges
- Lack of Awareness about the infection
The lack of awareness about these infections could curb the growth of the global vaginal anti infectives treatment market over a forecast period. Not much awareness about the infection leads to improper treatment thus restraining the market growth.
- High Cost
The huge expenditure associated with these agents surely hamper the market growth. Several antifungal, antiviral, antibacterial drugs are facing an increasing hike and thus is hampering the market growth.
This global vaginal anti infectives market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global vaginal anti infectives market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Vaginal Anti Infectives Market
The coronavirus pandemic has hindered the development, production, and supply of drugs and other healthcare products and affected numerous companies' growth of healthcare businesses globally. However, in the post-pandmeic era, the market is expected to grow because of an increase in R&D initiatives for exact diagnosis. Numerous government and non-government bodies, including the European Institute of Women's Health (EIWH) and the World Health Organization, have launched multiple public awareness campaigns about women's health.Thus, COVID-19 left a major imapact on the global vaginal anti infectives market.
Global Vaginal Anti Infectives Market Scope
The global vaginal anti infectives market is segmented on the basis of ttype, product, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Antifungal
- Fluconazole
- Clotrimazole
- Antibacterial
- Clindamycin
- Metronidazole
- Antiviral
- Others
Product
- Creams
- Pessaries (Tablets)
- Gels
- Solutions
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Vaginal Anti Infectives Market Regional Analysis/Insights
The global vaginal anti infectives market is analysed and market size insights and trends are provided by type, product, distribution channel and end-user as referenced above.
The major countries covered in the global vaginal anti infectives market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global vaginal anti infectives market throughout the forecasted period due increasing initiatives taken by the government and pharmaceutical organizations to spread awareness and increased prevalence of vaginal infection in women.
North America dominates the market due to increasing initiatives by pharmaceutical organizations to generate novel formulation and well-spread awareness of anti-infectives among end-users.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Vaginal Anti Infectives Market Share Analysis
The global vaginal anti infectives market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global vaginal anti infectives market.
Key players operating in the global vaginal anti infectives market include:
- Pfizer Inc (U.S.)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Hikma Pharmaceuticals plc (U.K.)
- Aurobindo Pharma (India)
- AbbVie Inc. (Ireland)
- Melinta Therapeutics, Inc (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Bayer AG (Germany)
- Lupin (India)
- Perrigo Company plc (U.S.)
SKU-